US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7247708B2
(en)
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
PL204285B1
(pl)
|
2000-02-11 |
2009-12-31 |
Bayer Healthcare Llc |
Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US6905683B2
(en)
|
2000-05-03 |
2005-06-14 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII variants
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
EP2226385B1
(de)
*
|
2000-09-13 |
2013-07-10 |
Novo Nordisk Health Care AG |
Varianten des menschlichen Koagulationsfaktors VII
|
RU2326126C2
(ru)
|
2000-09-13 |
2008-06-10 |
Ново Нордиск Хелт Кэр Аг |
Полипептид фактора vii свертывания крови, его получение и применение
|
WO2002038162A1
(en)
|
2000-11-09 |
2002-05-16 |
The Scripps Research Institute |
MODIFIED FACTOR VIIa
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
US7052868B2
(en)
|
2001-09-27 |
2006-05-30 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
EP1432794B1
(de)
*
|
2001-09-27 |
2011-11-09 |
Novo Nordisk Health Care AG |
Menschliche gerinnungsfaktor-vii-polypeptide
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US6960657B2
(en)
|
2001-11-02 |
2005-11-01 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
EP1451315B1
(de)
*
|
2001-11-02 |
2014-05-21 |
Novo Nordisk Health Care AG |
Menschliche gerinnungsfaktor-vii-polypeptide
|
JP2005511601A
(ja)
*
|
2001-11-09 |
2005-04-28 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第vii因子ポリペプチドおよび組織プラスミノゲン阻害剤を含む薬学的組成物
|
EP1446154A1
(de)
*
|
2001-11-09 |
2004-08-18 |
Novo Nordisk Health Care AG |
Pharmazeutische zusammensetzung mit faktor-vii-polypeptiden und alpha2 antiplasmin-polypeptiden
|
US7291587B2
(en)
|
2001-11-09 |
2007-11-06 |
Novo Nordisk Healthcare A/G |
Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
|
JP2005510515A
(ja)
*
|
2001-11-09 |
2005-04-21 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Vii因子ポリペプチドおよびプロテインc阻害剤を含む薬学的組成物
|
EP1446145A1
(de)
*
|
2001-11-09 |
2004-08-18 |
Novo Nordisk Health Care AG |
Pharmaceutische zusammensetzung die faktor vii und tafi enthält
|
WO2003039590A1
(en)
*
|
2001-11-09 |
2003-05-15 |
Novo Nordisk Health Care Ag |
Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides
|
US7078479B2
(en)
|
2001-11-09 |
2006-07-18 |
Novo Nordisk Healthcare A/G |
Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
|
PL370118A1
(en)
*
|
2001-11-09 |
2005-05-16 |
Novo Nordisk Health Care Ag |
Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
|
CN1607958A
(zh)
|
2001-12-21 |
2005-04-20 |
诺和诺德医疗保健公司 |
因子ⅶ多肽的液体组合物
|
JP2005523723A
(ja)
|
2002-04-30 |
2005-08-11 |
マキシゲン ホルディングス リミテッド |
第VII因子または第VIIa因子のポリペプチド変種
|
EP2283856B1
(de)
|
2002-06-21 |
2017-09-20 |
Novo Nordisk Health Care AG |
Stabiliserte feste Zusammensetzungen von Faktor VIIa Polypeptiden
|
JP4634145B2
(ja)
|
2002-06-21 |
2011-02-16 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
ペジル化されたvii因子糖形体
|
US6933136B2
(en)
|
2002-09-20 |
2005-08-23 |
Novo Nordisk A/S |
Method for making recombinant proteins
|
US6911323B2
(en)
|
2002-09-25 |
2005-06-28 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
ES2293088T3
(es)
|
2002-09-25 |
2008-03-16 |
Novo Nordisk Health Care Ag |
Polipeptidos del factor vii de la coagulacion humana.
|
EP1611236A1
(de)
|
2003-03-18 |
2006-01-04 |
Novo Nordisk Health Care AG |
Verfahren zur herstellung von serinproteasen mit gla-rest
|
DK2085470T3
(da)
|
2003-03-20 |
2012-08-06 |
Bayer Healthcare Llc |
FVII- eller FVIIa-varianter
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
KR101191779B1
(ko)
|
2003-06-19 |
2013-01-14 |
맥시겐 홀딩스 엘티디 |
인자 ⅶ 또는 ⅶ에이 지엘에이 도메인 변종들
|
ATE547114T1
(de)
*
|
2003-06-25 |
2012-03-15 |
Novo Nordisk Healthcare Ag |
Flüssige zusammensetzungen von factor vii polypeptiden
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
EP2392655A3
(de)
|
2003-09-09 |
2012-02-29 |
Novo Nordisk Health Care AG |
Gerinnungsfaktor VII Polypeptide
|
JP2007509843A
(ja)
|
2003-10-07 |
2007-04-19 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第VII/VIIa因子活性を有するハイブリッド分子
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
EP1711513B1
(de)
|
2003-12-01 |
2014-07-02 |
Novo Nordisk Health Care AG |
Nanofiltration von faktor vii lösungen zur entfernung von viren
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
EP2298287B1
(de)
|
2003-12-19 |
2018-04-11 |
Novo Nordisk Health Care AG |
Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
|
BRPI0506864A
(pt)
|
2004-01-21 |
2007-05-29 |
Novo Nordisk As |
método para conjugar peptìdeos, peptìdeo conjugado, composto e sais, pró-drogas e solvatos farmaceuticamente aceitáveis destes, composição farmacêutica, uso de um composto, e, método para tratamento de doença
|
EP1713906A2
(de)
*
|
2004-02-03 |
2006-10-25 |
Novo Nordisk Health Care AG |
Keine funktionelle lipid-membran-bindungsdomäne aufweisende koagulationsfaktor vii/viia-varianten
|
EP2586456B1
(de)
|
2004-10-29 |
2016-01-20 |
ratiopharm GmbH |
Umformung und GlycoPEGylierung des Fibroblastenwachstumsfaktors (FGF)
|
BRPI0519626A2
(pt)
|
2004-12-23 |
2009-02-25 |
Novo Nordisk Healthcare Ag |
mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse
|
AU2006203792B2
(en)
|
2005-01-10 |
2011-11-03 |
Ratiopharm Gmbh |
Glycopegylated Granulocyte Colony Stimulating Factor
|
EP2386571B1
(de)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
|
EP2975135A1
(de)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glykopegylierter Faktor IX
|
US8633300B2
(en)
|
2005-06-17 |
2014-01-21 |
Novo Nordisk Healthcare Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
WO2007006808A1
(en)
|
2005-07-13 |
2007-01-18 |
Novo Nordisk Health Care Ag |
Host cell protein knock-out cells for production of therapeutic proteins
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
ES2515915T3
(es)
|
2005-09-01 |
2014-10-30 |
Novo Nordisk Health Care Ag |
Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
|
EP1926817A2
(de)
|
2005-09-14 |
2008-06-04 |
Novo Nordisk Health Care AG |
Menschliche gerinnungsfaktor-vii-polypeptide
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
US20080280818A1
(en)
|
2006-07-21 |
2008-11-13 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
EP2059527B1
(de)
|
2006-09-01 |
2014-12-03 |
Novo Nordisk Health Care AG |
Modifizierte glykoproteine
|
EP2054521A4
(de)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Verfahren zur reinigung von polypeptid-konjugate
|
ES2655639T3
(es)
|
2006-12-15 |
2018-02-21 |
Baxalta GmbH |
Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
|
CN101796063B
(zh)
|
2007-04-03 |
2017-03-22 |
拉蒂奥法姆有限责任公司 |
使用糖聚乙二醇化g‑csf的治疗方法
|
SG174077A1
(en)
|
2007-04-13 |
2011-09-29 |
Catalyst Biosciences Inc |
Modified factor vii polypetides and uses thereof
|
CA2690611C
(en)
|
2007-06-12 |
2015-12-08 |
Novo Nordisk A/S |
Improved process for the production of nucleotide sugars
|
HRP20171375T1
(hr)
|
2007-12-27 |
2017-12-15 |
Baxalta GmbH |
Postupci s kulturama stanica
|
ES2476690T3
(es)
|
2008-02-27 |
2014-07-15 |
Novo Nordisk A/S |
Moléculas conjugadas del Factor VIII
|
TWI465247B
(zh)
|
2008-04-11 |
2014-12-21 |
Catalyst Biosciences Inc |
經修飾的因子vii多肽和其用途
|
MY184447A
(en)
|
2009-06-09 |
2021-04-01 |
Prolong Pharmaceuticals Llc |
Hemoglobin compositions
|
FR2947181B1
(fr)
*
|
2009-06-26 |
2012-05-04 |
Lfb Biotechnologies |
Composition de facteur vii
|
RU2744370C2
(ru)
|
2009-07-27 |
2021-03-05 |
Баксалта Инкорпорейтед |
Конъюгаты белков свертывания крови
|
US9795683B2
(en)
|
2009-07-27 |
2017-10-24 |
Lipoxen Technologies Limited |
Glycopolysialylation of non-blood coagulation proteins
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
NZ598056A
(en)
|
2009-07-27 |
2014-01-31 |
Baxter Int |
Blood coagulation protein conjugates
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
US9260518B2
(en)
|
2010-06-30 |
2016-02-16 |
Novo Nordisk A/S |
Antibodies that are capable of specifically binding tissue factor pathway inhibitor
|
PT2654794T
(pt)
|
2010-12-22 |
2020-06-11 |
Baxalta Inc |
Materiais e métodos para conjugação de um derivado de ácido gordo solúvel em água a uma proteína
|
EP2680875B1
(de)
|
2011-03-02 |
2019-10-23 |
Novo Nordisk Health Care AG |
Gerinnungsfaktor-targeting auf tlt-1 auf aktivierten plättchen
|
EP3527218A1
(de)
|
2011-06-10 |
2019-08-21 |
Bioverativ Therapeutics Inc. |
Gerinnungsfördernde verbindungen und verfahren zur verwendung davon
|
EP2554161A1
(de)
|
2011-08-02 |
2013-02-06 |
LFB Biotechnologies |
Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
|
WO2014057068A1
(en)
|
2012-10-10 |
2014-04-17 |
Novo Nordisk Health Care Ag |
Liquid pharmaceutical composition of factor vii polypeptide
|
JP2015533152A
(ja)
|
2012-10-15 |
2015-11-19 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
第vii因子コンジュゲート
|
AU2017206445B2
(en)
|
2016-01-15 |
2019-07-18 |
Rigshospitalet |
Quantitative pet imaging of tissue factor expression using 18F-labled active site inhibited factor VII
|
WO2021030787A1
(en)
|
2019-08-15 |
2021-02-18 |
Catalyst Biosciences, Inc. |
Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
|